Comparison Guide · Clinical Data
Tirzepatide vs Semaglutide: Full Comparison 2026
A head-to-head look at both GLP-1 medications — weight loss results, side effects, dosing, cost, and how to choose. Based on published clinical trial data.
💉 Mounjaro · Zepbound · Ozempic · Wegovy
📅 Updated May 2026
🔬 SURMOUNT & STEP trial data
Clinical trial results at maximum dose
Average weight loss in FDA pivotal trials
Semaglutide
Wegovy 2.4mg · STEP-1 trial
−14.9%
of body weight
⬆ Higher loss
Tirzepatide
Zepbound 15mg · SURMOUNT-1 trial
−20.9%
of body weight
STEP-1 (n=1,961, 68 weeks, BMI ≥30) vs SURMOUNT-1 (n=2,539, 72 weeks, BMI ≥30). Trials not directly comparable due to different populations and durations. Direct head-to-head data available from SURPASS-2, which showed tirzepatide's superiority in a T2D population.
How tirzepatide and semaglutide work differently
Both medications are weekly injectables, but they act through different receptors — and that difference explains why tirzepatide produces greater weight loss.
| Property |
Semaglutide |
Tirzepatide |
| Drug class | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Receptors targeted | GLP-1 only | GIP + GLP-1 (dual) |
| Brand names (obesity) | Wegovy | Zepbound |
| Brand names (diabetes) | Ozempic, Rybelsus | Mounjaro |
| FDA approval (obesity) | June 2021 | November 2023 |
| FDA approval (T2D) | December 2017 | May 2022 |
| Half-life | ~7 days | ~5 days |
| Injection frequency | Once weekly | Once weekly |
The GIP advantage
Semaglutide works solely on GLP-1 receptors, which slow gastric emptying, increase insulin secretion, and — crucially — reduce appetite signals to the brain. This single mechanism is powerful enough to produce an average ~15% weight loss in clinical trials.
Tirzepatide adds activation of the GIP (glucose-dependent insulinotropic polypeptide) receptor, which appears to amplify the appetite-suppressing effects in the hypothalamus and improve metabolic efficiency in fat tissue. The result is a substantially stronger signal to eat less, producing closer to 20% weight loss at maximum doses.
Key insight: Both drugs reduce appetite and slow digestion. Tirzepatide's dual mechanism produces greater hunger suppression on average, but individual responses vary significantly — some patients lose more weight on semaglutide than others do on tirzepatide.
Weight loss efficacy: what the clinical trials show
The most reliable comparison comes from the pivotal obesity trials (STEP-1 for semaglutide; SURMOUNT-1 for tirzepatide) and from SURPASS-2, which directly compared the two drugs head-to-head in type 2 diabetes patients.
| Trial |
Drug & Dose |
Duration |
Avg. weight loss |
≥5% responders |
| STEP-1 | Semaglutide 2.4mg | 68 weeks | −14.9% | 87% |
| SURMOUNT-1 | Tirzepatide 5mg | 72 weeks | −15.0% | 85% |
| SURMOUNT-1 | Tirzepatide 10mg | 72 weeks | −19.5% | 89% |
| SURMOUNT-1 | Tirzepatide 15mg | 72 weeks | −20.9% | 91% |
| SURPASS-2 (T2D) | Semaglutide 1mg | 40 weeks | −5.7% | — |
| SURPASS-2 (T2D) | Tirzepatide 15mg | 40 weeks | −11.2% | — |
In SURPASS-2 — the only trial to directly pit the two drugs against each other — tirzepatide at all three doses (5mg, 10mg, 15mg) produced significantly greater A1c reductions and weight loss than semaglutide 1mg. Note that semaglutide 1mg is the diabetes dose; the obesity dose (2.4mg via Wegovy) was not tested in that trial.
Cardiovascular outcomes: Semaglutide has a larger evidence base for heart protection. The SELECT trial (2023) showed semaglutide reduced major adverse cardiovascular events by 20% in people with obesity and established cardiovascular disease. Tirzepatide's SURMOUNT-MMO cardiovascular outcomes trial results are anticipated in 2026.
What about non-responders?
Roughly 10–15% of patients on either drug lose less than 5% of body weight. The reason is not well understood but likely involves genetic variation in GLP-1 receptor sensitivity. There is no reliable way to predict response before starting — which is why providers typically recommend a 12–16 week trial period to assess whether a drug is working for a given patient.
Side effects: how do they compare?
Because both drugs activate the GLP-1 receptor, their side effect profiles are nearly identical. GI symptoms are the most common issue and are usually worst during dose escalation.
| Side effect |
Semaglutide |
Tirzepatide |
Notes |
| Nausea | 44% | 31–39% | Most common; peaks during escalation |
| Diarrhea | 30% | 17–23% | Usually resolves at maintenance dose |
| Constipation | 24% | 11–17% | Slower gastric emptying effect |
| Vomiting | 24% | 9–13% | Reason for stopping in ~5% of patients |
| Fatigue | 11% | ~10% | Especially during first weeks |
| Gallbladder issues | ~2.6% | ~0.6% | Rapid weight loss increases gallstone risk |
| Pancreatitis | Rare (<0.1%) | Rare (<0.1%) | Contraindicated with history of pancreatitis |
| Injection site reactions | Common | Common | Rotate sites to minimise |
| Thyroid C-cell tumours | Black box warning* | Black box warning* | *In rodents; human risk unknown |
Side effect percentages are from FDA labeling (placebo-adjusted, at maximum approved doses). The key takeaway: both drugs have very similar tolerability profiles. The main practical difference is that semaglutide's slightly longer half-life means nausea can linger longer between doses, while tirzepatide's faster clearance may provide a bit more relief by injection day.
Minimising GI side effects: Eat smaller, lower-fat meals. Avoid high-fat, spicy, or ultra-processed foods in the first hours after injection. Stay hydrated. Most GI side effects resolve significantly within 4–8 weeks once you reach a stable dose.
Dosing schedules compared
Both drugs are injected subcutaneously once per week. The escalation schedules differ in total duration and number of steps.
| Weeks |
Semaglutide (Wegovy) |
Tirzepatide (Zepbound) |
| Weeks 1–4 | 0.25mg | 2.5mg |
| Weeks 5–8 | 0.5mg | 5mg |
| Weeks 9–12 | 1.0mg | 7.5mg |
| Weeks 13–16 | 1.7mg | 10mg |
| Week 17+ | 2.4mg (maintenance) | 12.5mg |
| Week 21+ | — | 15mg (maintenance) |
| Time to max dose | ~16 weeks | ~20 weeks |
| Injection device | Pre-filled pen | Pre-filled pen |
Tirzepatide has one additional escalation step, meaning patients take slightly longer to reach maximum dose. Both schedules are designed to minimise GI side effects by letting the body adapt gradually. Providers may extend any step if GI symptoms are poorly tolerated — there is no clinical penalty for slower escalation.
Compounded versions of both drugs follow the same escalation principles but may be dispensed as multi-dose vials, requiring the patient to draw their own dose with an insulin syringe. Use the vial units calculator if you're on a compounded version.
Cost in 2026: brand vs compounded
Cost is often the deciding factor between the two drugs. With insurance coverage for GLP-1s tightening in 2025–2026, most patients are paying out of pocket or through telehealth providers offering compounded versions.
| Option |
Drug |
Est. monthly cost |
Notes |
| Brand (retail, no insurance) | Wegovy (semaglutide) | ~$1,349 | Manufacturer savings card may reduce to ~$650 for insured patients |
| Brand (retail, no insurance) | Zepbound (tirzepatide) | ~$1,059 | Eli Lilly's self-pay price was ~$550 via direct program |
| Brand (with good insurance) | Either | $0–$150 | Varies widely; many plans now exclude GLP-1s |
| Compounded semaglutide | Telehealth providers | $146–$299 | FDA shortage period; availability may change — verify current status |
| Compounded tirzepatide | Telehealth providers | $199–$399 | As above — confirm availability with provider |
Important note on compounded GLP-1s: Compounded semaglutide and tirzepatide are not FDA-approved as finished drug products. They are prepared by licensed 503A/503B pharmacies. FDA removed both drugs from the shortage list in 2025, which restricts compounding availability. Always confirm with your telehealth provider before committing to a treatment plan.
Compare GLP-1 provider prices
Licensed telehealth — prescription, shipping, and medical evaluation included.
Compare all 7 providers →
Sponsored · Compounded GLP-1 not FDA-approved as finished drug · Prices confirmed at intake
Category-by-category scorecard
💪 Weight loss (avg. max dose)
🤢 GI tolerability
Slightly better ✓
31–39% nausea
📋 Insurance coverage
Broader ✓
Longer on market
Who should choose which?
Neither drug is universally "better" — the right choice depends on your specific situation, goals, and what your provider determines is appropriate.
Consider semaglutide if you:
- Have established cardiovascular disease (the SELECT trial evidence is compelling)
- Have had good insurance coverage or access to lower-cost Wegovy programs
- Prefer an oral option — Rybelsus is available for diabetes management
- Have had GI issues on tirzepatide in the past
- Are earlier in your medication journey and want to start with the more established drug
Consider tirzepatide if you:
- Have struggled to reach weight loss goals on semaglutide
- Want to maximise expected weight loss (the trial data are clear on superiority)
- Have type 2 diabetes and need strong A1c reduction
- Are paying out of pocket and can access compounded tirzepatide at competitive pricing
- Found nausea on semaglutide to be persistent (tirzepatide's shorter half-life may help)
The bottom line: If your only goal is maximum weight loss and cost isn't the deciding factor, the clinical trial data support tirzepatide. If you have cardiovascular disease or cost is a concern, semaglutide is a well-proven choice. For most people, either drug will produce meaningful results — and the best drug is the one you can access, afford, and tolerate.
Ready to start?
Get GLP-1 medication from $146/month
Licensed telehealth providers — medical evaluation, prescription, and 2-day shipping included. Both semaglutide and tirzepatide available.
We may earn a commission from provider links. This doesn't influence our content.
Frequently asked questions
Is tirzepatide more effective than semaglutide for weight loss?+
Yes, based on clinical trial data. The SURMOUNT-1 trial showed tirzepatide 15mg produced an average 20.9% weight reduction, compared to 14.9% with semaglutide 2.4mg in the STEP-1 trial. The SURPASS-2 trial directly compared both drugs and confirmed tirzepatide's superiority in type 2 diabetes patients at all doses tested. That said, individual responses vary — some patients lose significantly more on semaglutide than others do on tirzepatide.
What is the key difference between tirzepatide and semaglutide?+
The primary difference is mechanism. Semaglutide activates only the GLP-1 receptor, which reduces appetite and slows digestion. Tirzepatide activates both the GLP-1 receptor and the GIP receptor — a dual action that produces stronger appetite suppression and better metabolic outcomes in most patients. This dual mechanism is why tirzepatide consistently outperforms semaglutide in head-to-head comparisons.
Which is cheaper — tirzepatide or semaglutide?+
Without insurance, brand-name Wegovy (semaglutide) costs approximately $1,349/month and Zepbound (tirzepatide) costs approximately $1,059/month. However, most patients accessing GLP-1s through telehealth use compounded versions: compounded semaglutide typically runs $146–$299/month, while compounded tirzepatide is $199–$399/month. Check provider availability carefully, as FDA compounding restrictions may affect access.
Do tirzepatide and semaglutide have the same side effects?+
Side effect profiles are very similar because both activate the GLP-1 receptor. Nausea, diarrhea, constipation, and vomiting are the most common for both, primarily during dose escalation. Tirzepatide reports slightly lower rates of nausea and vomiting in trial data, possibly because its shorter half-life (~5 days vs ~7 days) means peak concentrations don't persist as long. Both are generally well tolerated once patients reach a stable maintenance dose.
Can you switch from semaglutide to tirzepatide?+
Yes, switching is common and generally safe under medical supervision. Most providers recommend starting tirzepatide at the lowest dose (2.5mg) regardless of what semaglutide dose you were on, to allow your body to adjust to the new molecule and its dual receptor activity. Because semaglutide has a ~7-day half-life, some overlap is unavoidable but is not a clinical concern. Many patients switch after plateauing on semaglutide and see renewed weight loss on tirzepatide.
Which GLP-1 is FDA-approved for weight loss?+
Both are FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition. Semaglutide 2.4mg (Wegovy) received approval in June 2021. Tirzepatide 5–15mg (Zepbound) received approval in November 2023. Their lower-dose diabetes counterparts — Ozempic and Mounjaro — are approved for type 2 diabetes and are frequently prescribed off-label for weight loss.